

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:sssptal814txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 12 Match STN Content and Features to Your Information  
Needs, Quickly and Conveniently  
NEWS 3 JAN 25 Annual Reload of MEDLINE database  
NEWS 4 FEB 16 STN Express Maintenance Release, Version 8.4.2, Is  
Now Available for Download  
NEWS 5 FEB 16 Derwent World Patents Index (DWPI) Revises Indexing  
of Author Abstracts  
NEWS 6 FEB 16 New FASTA Display Formats Added to USGENE and PCTGEN  
NEWS 7 FEB 16 INPADOCDB and INPAFAMDB Enriched with New Content  
and Features  
NEWS 8 FEB 16 INSPEC Adding Its Own IPC codes and Author's E-mail  
Addresses  
NEWS 9 APR 02 CAS Registry Number Crossover Limits Increased to  
500,000 in Key STN Databases  
NEWS 10 APR 02 PATDPAFULL: Application and priority number formats  
enhanced  
NEWS 11 APR 02 DWPI: New display format ALLSTR available  
NEWS 12 APR 02 New Thesaurus Added to Derwent Databases for Smooth  
Sailing through U.S. Patent Codes  
NEWS 13 APR 02 EMBASE Adds Unique Records from MEDLINE, Expanding  
Coverage back to 1948  
NEWS 14 APR 07 CA/Caplus CLASS Display Streamlined with Removal of  
Pre-IPC 8 Data Fields  
NEWS 15 APR 07 50,000 World Traditional Medicine (WTM) Patents Now  
Available in Caplus  
NEWS 16 APR 07 MEDLINE Coverage Is Extended Back to 1947  
NEWS 17 JUN 16 WPI First View (File WPIFV) will no longer be  
available after July 30, 2010  
NEWS 18 JUN 18 DWPI: New coverage - French Granted Patents  
NEWS 19 JUN 18 CAS and FIZ Karlsruhe announce plans for a new  
STN platform  
NEWS 20 JUN 18 IPC codes have been added to the INSPEC backfile  
(1969-2009)  
NEWS 21 JUN 21 Removal of Pre-IPC 8 data fields streamline displays  
in CA/Caplus, CASREACT, and MARPAT  
NEWS 22 JUN 21 Access an additional 1.8 million records exclusively  
enhanced with 1.9 million CAS Registry Numbers --  
EMBASE Classic on STN

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,  
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:54:27 ON 21 JUN 2010

```
=> file medline hcaplus biosis biotechds scisearch embase
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                    ENTRY      SESSION
FULL ESTIMATED COST                               0.22          0.22
```

FILE 'MEDLINE' ENTERED AT 13:55:14 ON 21 JUN 2010

FILE 'HCAPLUS' ENTERED AT 13:55:14 ON 21 JUN 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:55:14 ON 21 JUN 2010  
Copyright (c) 2010 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 13:55:14 ON 21 JUN 2010  
COPYRIGHT (C) 2010 THOMSON REUTERS

FILE 'SCISEARCH' ENTERED AT 13:55:14 ON 21 JUN 2010  
Copyright (c) 2010 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:55:14 ON 21 JUN 2010  
Copyright (c) 2010 Elsevier B.V. All rights reserved.

```
=> s (pyrroloquinoline quinone glucose dehydrogenase or PQQGDH) and cytochrome
L1      24 (PYRROLOQUINOLINE QUINONE GLUCOSE DEHYDROGENASE OR PQQGDH) AND
        CYTOCHROME
```

```
=> dup rem l1
PROCESSING COMPLETED FOR L1
L2      11 DUP REM L1 (13 DUPLICATES REMOVED)
```

```
=> d l2 1-11 ibib ab
```

```
L2  ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:  2009:385390 HCAPLUS Full-text
DOCUMENT NUMBER:  150:359900
TITLE:            Access disconnect detection using glucose and method
                  of detecting blood leakage
INVENTOR(S):      Rohde, Justin B.
PATENT ASSIGNEE(S):  Baxter International Inc., USA; Baxter Healthcare S.
                  A.
SOURCE:           PCT Int. Appl., 27pp.; Chemical Indexing Equivalent to
```

150:359881 (US)

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009042260	A1	20090402	WO 2008-US66092	20080606
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GD, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20090082653	A1	20090326	US 2007-860071	20070924
CA 2698733	A1	20090402	CA 2008-2698733	20080606
EP 2195046	A1	20100616	EP 2008-770310	20080606
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				

PRIORITY APPLN. INFO.:

US 2007-860071

A

20070924

WO 2008-US66092

W

20080606

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB An access disconnect sensor for a patient undergoing extracorporeal blood processing includes an electrochem. fuel cell or sensor to detect blood leakage. The fuel cell includes circuitry for oxidizing glucose in the blood. The sensor also includes a transmitter to send a signal to a remote receiver that the sensor indicates the presence of blood. The circuitry may include a battery or may use electricity generated by the sensor to send a signal indicating a leak of blood or disconnection of the access needle.

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2010 ACS ON STN

ACCESSION NUMBER:

2009:363962 HCAPLUS Full-text

DOCUMENT NUMBER:

150:359881

TITLE:

Access disconnect detection using glucose and method of detecting blood leakage

INVENTOR(S):

Rohde, Justin B.

PATENT ASSIGNEE(S):

Baxter International Inc., USA; Baxter Healthcare S.A.

SOURCE:

U.S. Pat. Appl. Publ., 15pp.; Chemical Indexing

Equivalent to 150:359900 (WO)

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090082653	A1	20090326	US 2007-860071	20070924
CA 2698733	A1	20090402	CA 2008-2698733	20080606

WO 2009042260	A1	20090402	WO 2008-US66092	20080606
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 2195046	A1	20100616	EP 2008-770310	20080606
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS			
US 20090105627	A1	20090423	US 2008-337300	20081217
PRIORITY APPLN. INFO.:			US 2007-860071	A 20070924
			WO 2008-US66092	W 20080606

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB An access disconnect sensor for a patient undergoing extracorporeal blood processing includes an electrochem. fuel cell or sensor to detect blood leakage. The fuel cell includes circuitry for oxidizing glucose in the blood. The sensor also includes a transmitter to send a signal to a remote receiver that the sensor indicates the presence of blood. The circuitry may include a battery or may use electricity generated by the sensor to send a signal indicating a leak of blood or disconnection of the access needle.

L2 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2010 ACS ON STN DUPLICATE 1

ACCESSION NUMBER: 2007:78986 HCAPLUS Full-text  
DOCUMENT NUMBER: 146:311784  
TITLE: The application of engineered glucose dehydrogenase to a direct electron-transfer-type continuous glucose monitoring system and a compartmentless biofuel cell  
AUTHOR(S): Okuda, J.; Yamazaki, T.; Fukasawa, M.; Kakehi, N.; Sode, K.  
CORPORATE SOURCE: Biomaterials Center, National Institute for Materials Science (NIMS), Tsukuba, Ibaraki, Japan  
SOURCE: Analytical Letters (2007), 40(3), 431-440  
CODEN: ANALBP; ISSN: 0003-2719  
PUBLISHER: Taylor & Francis, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Continuous glucose monitoring (CGM) is expected to become an ideal way to monitor glycemic levels in diabetic patients. Biofuel cells can be used as an alternative energy source in future implantable devices, such as implantable glucose sensors in the artificial pancreas. Glucose dehydrogenase from *Acinetobacter calcoaceticus*, which harbors pyrroloquinoline quinone as the prosthetic group (PQQGDH), is one of the enzymes most attractive as a glucose sensor constituent and as the anode enzyme in biofuel cells, due to its high catalytic activity and insensitivity to oxygen. However, the application of PQQGDH for these purposes is inherently limited because an electron mediator is required for the electron transfer to the electrode. The authors have recently reported on the development of an engineered enzyme, quinoxinohemoprotein glucose dehydrogenase (QH-GDH), in which the cytochrome c domain of the quinoxinohemoprotein ethanol dehydrogenase (QH-EDH) was fused with PQQGDH, to enable electron transfer to the electrode in the absence of an artificial mediator. In this study, the authors constructed a direct electron-transfer-type CGM system employing QH-GDH. This CGM system showed sufficient

current response and high operational stability. Furthermore, the authors successfully constructed a compartmentless biofuel cell employing QH-GDH. OS.CITING  
 REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD

(6 CITINGS)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2010 ACS ON STN DUPLICATE 2

ACCESSION NUMBER: 2005:300480 HCAPLUS Full-text

DOCUMENT NUMBER: 142:370305

TITLE: Glucose dehydrogenase/cytochrome fusion  
 protein for glucose sensor

INVENTOR(S): Sode, Koji

PATENT ASSIGNEE(S): Japan

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030807	A1	20050407	WO 2004-JP14575	20040928
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2421951	A	20060712	GB 2006-6955	20040928
GB 2421951	B	20080227		
US 20070267301	A1	20071122	US 2006-574085	20060330
PRIORITY APPLN. INFO.:			JP 2003-340092	A 20030930
			WO 2004-JP14575	W 20040928

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A pyrroloquinolinequinone glucose dehydrogenase (PQQGDH)/ cytochrome fusion protein is disclosed. As PQQGDH, an use can be made of, for example, water-soluble PQQGDH derived from *Acinetobacter calcoaceticus*. As cytochrome, an use can be made of, for example, an electron transport domain of quinoxemoprotein ethanol dehydrogenase of *Comamonas testosteroni*. In this fusion protein, an intramol. electron transfer from PQQ being an oxidation-reduction center to cytochrome occurs. Accordingly, a direct electron transport-type glucose sensor not needing any electron mediator can be produced by the use of the fusion protein.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2010 ACS ON STN DUPLICATE 3

ACCESSION NUMBER: 2004:702629 HCAPLUS Full-text

DOCUMENT NUMBER: 142:151093

TITLE: Engineered PQQ glucose dehydrogenase-based enzyme  
 sensor for continuous glucose monitoring

AUTHOR(S): Okuda, Junko; Wakai, Junko; Igarashi, Satoshi; Sode,  
 Koji

CORPORATE SOURCE: Department of Biotechnology, Faculty of Technology,  
Tokyo University of Agriculture and Technology, Tokyo,  
Japan

SOURCE: Analytical Letters (2004), 37(9), 1847-1857  
CODEN: ANALBP; ISSN: 0003-2719

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Continuous glucose monitoring (CGM) is expected to become an ideal way to monitor the glycemic level of diabetic patients. A recent trend in the disposable self blood glucose sensing development has been the use of pyrroloquinoline quinone-harboring glucose dehydrogenase (PQQGDH). However, due to a number of limitations of PQQGDH, conventionally utilized glucose oxidase (GOD) remains widely utilized in CGM. Two major problems that arose in the application of PQQGDH for CGM are the poor stability and its requirement for artificial electron acceptors for electrochem. measurement. To solve these problems, we investigated the amenability of our engineered PQQGDH Ser415Cys, which has a far superior thermal stability over the wild-type enzyme, for the CGM system, and the applicability of cyt b562 as the electron mediator to construct a CGM system free of synthetic mediator. As a result, the operational stability of CGM system employing Ser415Cys co-immobilized with cyt b562 was far superior to that of the wild-type enzyme-based electrode, with more than 60% of the initial response observed after 72 h at 37°. We achieved the successful application of PQQGDH in continuous operation without a significant decrease in the sensor signal. OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD

(4 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 11 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN  
DUPLICATE 4

ACCESSION NUMBER: 2004:173352 BIOSIS Full-text

DOCUMENT NUMBER: PREV200400174897

TITLE: PQQ glucose dehydrogenase with novel electron transfer ability.

AUTHOR(S): Okuda, Junko; Sode, Koji [Reprint Author]

CORPORATE SOURCE: Department of Biotechnology, Faculty of Technology, Tokyo  
University of Agriculture and Technology, 2-24-16  
Nakamachi, Koganei, Tokyo, 184-8588, Japan  
sode@cc.tuat.ac.jp

SOURCE: Biochemical and Biophysical Research Communications,  
(February 13 2004) Vol. 314, No. 3, pp. 793-797. print.  
CODEN: BBRCA9. ISSN: 0006-291X.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 31 Mar 2004

Last Updated on STN: 31 Mar 2004

AB PQQ glucose dehydrogenase from *Acinetobacter calcoaceticus* (GDH-B) is one of the most industrially attractive enzymes, as a sensor constituent for glucose sensing, because of its high catalytic activity and insensitivity to oxygen. We attempted to engineer GDH-B to enable electron transfer to the electrode in the absence of artificial electron mediator by mimicking the domain structure of the quinohemoprotein ethanol dehydrogenase (QH-EDH) from *Comamonas testosteroni*, which is composed of a PQQ-containing catalytic domain and a cytochrome c domain. We genetically fused the cytochrome c domain of QH-EDH to the C-terminal of GDH-B. The constructed fusion protein showed not only intra-molecular electron transfer, between PQQ and heme of the cytochrome c domain, but also electron transfer from heme to the electrode, thereby allowing the construction of a direct electron transfer-type glucose sensor.

L2 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2004:542873 HCAPLUS Full-text

DOCUMENT NUMBER: 141:273433

TITLE: Molecular engineering of PQQGDH and its applications

AUTHOR(S): Igarashi, Satoshi; Okuda, Junko; Ikebukuro, Kazunori; Sode, Koji

CORPORATE SOURCE: National Institute for Materials Science, 1-1, Namiki, Tsukuba, Ibaraki, 305-0044, Japan

SOURCE: Archives of Biochemistry and Biophysics (2004), 428(1), 52-63

CODEN: ABBIA4; ISSN: 0003-9861

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Pyrroloquinolinequinone glucose dehydrogenases (PQQGDHs) are the most industrially attractive enzymes, especially PQQGDH-B employing glucose sensors are already in the market. To develop an ideal glucose sensor enzyme, therefore we have constructed and characterized several engineered PQQGDH-Bs. The engineered enzymes will give effective information about unknown properties on PQQGDH-B such as reaction mechanism, substrate inhibition system, and neg. cooperativity. Of equal importance, the application of the thermostable PQQGDH-B is not limited to the development of continuous glucose monitoring system, biofuel cell, and DNA sensors. In addition, co-immobilizing electron transfer protein such as cytochrome c and cytochrome b562, we have developed the sensor system that showed 30-fold greater response. Furthermore, mimicking the domain structure of QH-EDH, we constructed fusion protein, QH-GDH, allowing the construction of a direct electron transfer-type glucose sensor. To the future, combining the engineered PQQGDH-B with the application of cytochromes instead of artificial electron mediator, we will construct and develop the ideal glucose sensor and other applications. OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS

RECORD (17 CITINGS)

REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 8 OF 11 MEDLINE on STN DUPLICATE 6

ACCESSION NUMBER: 2003187562 MEDLINE Full-text

DOCUMENT NUMBER: PubMed ID: 12706581

TITLE: Glucose enzyme electrode using cytochrome b(562) as an electron mediator.

AUTHOR: Okuda Junko; Wakai Junko; Yuhashi Noriko; Sode Koji

CORPORATE SOURCE: Department of Biotechnology, Faculty of Technology, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, 184-8588, Tokyo, Japan.

SOURCE: Biosensors & bioelectronics, (2003 May) Vol. 18, No. 5-6, pp. 699-704.

Journal code: 9001289. ISSN: 0956-5663. L-ISSN: 0956-5663.

PUB. COUNTRY: England; United Kingdom

DOCUMENT TYPE: (COMPARATIVE STUDY) (EVALUATION STUDIES)

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200404

ENTRY DATE: Entered STN: 23 Apr 2003

Last Updated on STN: 14 Apr 2004

Entered Medline: 13 Apr 2004

AB We demonstrate the construction of glucose sensors employing pyrroloquinoline quinone (PQQ) glucose dehydrogenase (PQQGDH) from *Acinetobacter calcoaceticus*

and glucose oxidase (GOD) from *Aspergillus niger* coupled with *Escherichia coli* soluble cytochrome b(562) (cyt b(562)) as electron acceptor. PQGGDH and GOD do not show direct electrochemical recycling of the prosthetic group at the electrode surface leading to a corresponding current signal. We constructed PQGGDH and GOD electrodes co-immobilized with 100-fold molar excess of cyt b(562) and investigated the electrochemical properties without synthetic electron mediators. PQGGDH/cyt b(562) and GOD/cyt b(562) electrodes both responded well to glucose whereas no current increase was observed from the electrode immobilizing enzyme alone. The detection limits for the PQGGDH/cyt b(562) and GOD/cyt b(562) electrodes were 0.1 and 0.8 mM, respectively, and their linearity extended to over 2 and 9 mM, respectively. These results demonstrate that a sensor system can be constructed without a synthetic electron mediator by using a natural electron acceptor. Furthermore, we have demonstrated the potential application of cyt b(562) in direct electron transfer type sensor systems with oxidoreductases whose quaternary structure do not contain any electron transfer subunit.

L2 ANSWER 9 OF 11 BIOTECHDS COPYRIGHT 2010 THOMSON REUTERS on STN

ACCESSION NUMBER: 2003-03957 BIOTECHDS Full-text

TITLE: Oxygen (enzyme) electrodes based on oxidoreductase and electron transfer protein, applicable in (bio)sensors e.g. for measuring serum glucose value as well as cholesterol and fructosylamine concentrations; enzyme immobilization on enzyme electrode for biosensor construction and oxygen analysis

AUTHOR: SODE K

PATENT ASSIGNEE: SODE K

PATENT INFO: WO 2002/73181 19 Sep 2002

APPLICATION INFO: WO 2002-JP2191 8 Mar 2002

PRIORITY INFO: JP 2001-281985 17 Sep 2001; JP 2001-70421 13 Mar 2001

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

OTHER SOURCE: WPI: 2002-713526 [77]

AB DERWENT ABSTRACT:

NOVELTY - An enzyme electrode containing an oxidoreductase and an electron transfer protein.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) sensors using the enzyme electrode as the working electrode; and (2) similar sensors with the glucose dehydrogenase and cytochrome c, or glucose dehydrogenase and cytochrome b562, chemically crosslinked onto the electrode when fabricated.

USE - The electrodes are applicable in (bio)sensors e.g. for measuring serum glucose value as well as cholesterol and fructosylamine concentrations.

ADVANTAGE - The electrodes can provide high response current value. EXAMPLE - After immobilization of PQGGDH and cytochrome c onto an electrode, the required enzyme electrode was constructed for producing a sensor for e.g. measuring glucose concentration in serum, with high response current value to glucose. (44 pages)

L2 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 2002:678725 HCAPLUS Full-text

DOCUMENT NUMBER: 138:234262

TITLE: The application of cytochromes as the interface molecule to facilitate the electron transfer for PQQ glucose dehydrogenase employing mediator type glucose sensor

AUTHOR(S): Okuda, Junko; Wakai, Junko; Sode, Koji

CORPORATE SOURCE: Department of Biotechnology, Faculty of Technology, Tokyo University of Agriculture and Technology, Tokyo,



184-8588, Japan  
SOURCE: Analytical Letters (2002), 35(9), 1465-1478  
CODEN: ANALBP; ISSN: 0003-2719  
PUBLISHER: Marcel Dekker, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB In order to improve the sensor response of mediator-type glucose enzyme electrode, we focused on the application of the electron transfer proteins, cytochromes, as interface mols. to facilitate the electron transfer from enzyme to artificial electron mediator. In this paper we used cytochrome c and cytochrome b562 for the improvement of sensor signal of glucose enzyme sensor employing glucose dehydrogenase harboring pyrroloquinoline quinone (PQQGDH). When sensors were operated using either potassium ferricyanide or 1-methoxy-5-methylphenazinium methylsulfate (mPMS) as the artificial electron mediator, the response was over 30-fold greater with the co-immobilization of either cytochrome c or cytochrome b562 than with PQQGDH alone. The impact of the cytochrome co-immobilization was dependent on the amount of cytochromes, indicating that these cytochromes facilitated the electron transfer from the PQQGDH redox center to the artificial electron mediators used in the sensor system. These results demonstrated the future application of cytochromes as an essential component for the improvement of sensor response in the redox enzymebased amperometric sensors.

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS  
RECORD (10 CITINGS)  
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:416272 HCAPLUS Full-text

DOCUMENT NUMBER: 131:181587

TITLE: Subunit analyses of a novel thermostable glucose dehydrogenase showing different temperature properties according to its quaternary structure  
AUTHOR(S): Yamazaki, Tomohiko; Tsugawa, Wakako; Sode, Koji  
CORPORATE SOURCE: Department of Biotechnology, Faculty of Technology, Tokyo University of Agriculture and Technology, Tokyo, 184-8588, Japan

SOURCE: Applied Biochemistry and Biotechnology (1999), 77-79(Twentieth Symposium on Biotechnology for Fuels and Chemicals, 1998), 325-335  
CODEN: ABIBDL; ISSN: 0273-2289

PUBLISHER: Humana Press Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors previously reported a novel glucose dehydrogenase (GDH) from the moderate thermophilic bacterium SM4 showing 2 peaks of optimum reaction temperature at .apprx.45° and at .apprx.75°. The resp. temperature peaks were found to derive (1) from a heterooligomeric enzyme constructed from 2 distinct peptides with an  $\alpha$  subunit (67 kDa) and  $\beta$  subunit (43 kDa), and (2) a single peptide enzyme containing only an  $\alpha$  subunit. The function of the 2 subunits in this GDH and their role in altering the temperature properties was investigated. The results of spectroscopic analyses indicated that the  $\alpha$  subunit contained an unknown cofactor exhibiting specific fluorescence spectra similar to that of pyrroloquinoline quinone (PQQ), and that the  $\beta$  subunit was cytochrome c. Thus, the  $\alpha$  subunit contains the catalytic center for glucose oxidation and the  $\beta$  subunit is an electron mediator. The results of urea denaturation and reconstitution experiment suggested that the dissociation of the heterooligomeric complex to a single peptide was reversible. Kinetic parameter analyses for glucose and the electron mediator also suggested that the  $\beta$  subunit was responsible for electron transfer from the catalytic center of the  $\alpha$  subunit to the electron mediator. The reason for the alteration of the temperature

properties of GDH was the dissociation of the electron-transferring  $\beta$  subunit. The  $\alpha$  subunit possessed high thermal stability, so that the optimum reaction temperature of the single-peptide GDH shifted to a higher temperature OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD

(8 CITINGS)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (glucose dehydrogenase or PQQGDH) and cytochrome  
L3 432 (GLUCOSE DEHYDROGENASE OR PQQGDH) AND CYTOCHROME

=> dup rem l3  
PROCESSING COMPLETED FOR L3  
L4 251 DUP REM L3 (181 DUPLICATES REMOVED)

=> s l4 and fusion  
L5 15 L4 AND FUSION

=> d 15 1-15 ibib ab

L5 ANSWER 1 OF 15 MEDLINE on STN  
ACCESSION NUMBER: 2004041270 MEDLINE Full-text  
DOCUMENT NUMBER: PubMed ID: 14741705  
TITLE: PQQ glucos dehydrogenase with novel  
electron transfer ability.  
AUTHOR: Okuda Junko; Sode Koji  
CORPORATE SOURCE: Department of Biotechnology, Faculty of Technology, Tokyo  
University of Agriculture and Technology, 2-24-16  
Nakamachi, Koganei, 184-8588, Tokyo, Japan.  
SOURCE: Biochemical and biophysical research communications, (2004  
Feb 13) Vol. 314, No. 3, pp. 793-7.  
Journal code: 0372516. ISSN: 0006-291X. L-ISSN: 0006-291X.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200403  
ENTRY DATE: Entered STN: 27 Jan 2004  
Last Updated on STN: 18 Mar 2004  
Entered Medline: 17 Mar 2004

AB PQQ glucos dehydrogenase from Acinetobacter calcoaceticus (GDH-B) is one of the most industrially attractive enzymes, as a sensor constituent for glucose sensing, because of its high catalytic activity and insensitivity to oxygen. We attempted to engineer GDH-B to enable electron transfer to the electrode in the absence of artificial electron mediator by mimicking the domain structure of the quinohemoprotein ethanol dehydrogenase (QH-EDH) from Comamonas testosteroni, which is composed of a PQQ-containing catalytic domain and a cytochrome c domain. We genetically fused the cytochrome c domain of QH-EDH to the C-terminal of GDH-B. The constructed fusion protein showed not only intra-molecular electron transfer, between PQQ and heme of the cytochrome c domain, but also electron transfer from heme to the electrode, thereby allowing the construction of a direct electron transfer-type glucose sensor.

L5 ANSWER 2 OF 15 MEDLINE on STN  
ACCESSION NUMBER: 1999106650 MEDLINE Full-text  
DOCUMENT NUMBER: PubMed ID: 9889976  
TITLE: The biochemistry, physiology and genetics of PQQ and  
PQQ-containing enzymes.

AUTHOR: Goodwin P M; Anthony C  
 CORPORATE SOURCE: Division of Biochemistry and Molecular Biology, School of Biological Sciences, University of Southampton, UK.  
 CONTRACT NUMBER: (United Kingdom Wellcome Trust)  
 SOURCE: Advances in microbial physiology, (1998) Vol. 40, pp. 1-80.  
 Ref: 221  
 Journal code: 0117147. ISSN: 0065-2911. L-ISSN: 0065-2911.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)  
 General Review; (REVIEW)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199902  
 ENTRY DATE: Entered STN: 16 Feb 1999  
 Last Updated on STN: 16 Feb 1999  
 Entered Medline: 2 Feb 1999

AB Pyrrolo-quinoline quinone (PQQ) is the non-covalently bound prosthetic group of many quinoproteins catalysing reactions in the periplasm of Gram-negative bacteria. Most of these involve the oxidation of alcohols or aldose sugars. PQQ is formed by fusion of glutamate and tyrosine, but details of the biosynthetic pathway are not known; a polypeptide precursor in the cytoplasm is probably involved, the completed PQQ being transported into the periplasm. In addition to the soluble methanol dehydrogenase of methylotrophs, there are three classes of alcohol dehydrogenases; type I is similar to methanol dehydrogenase; type II is a soluble quinohaemoprotein, having a C-terminal extension containing haem C; type III is similar but it has two additional subunits (one of which is a multihaem cytochrome c), bound in an unusual way to the periplasmic membrane. There are two types of glucose dehydrogenase; one is an atypical soluble quinoprotein which is probably not involved in energy transduction. The more widely distributed glucose dehydrogenases are integral membrane proteins, bound to the membrane by transmembrane helices at the N-terminus. The structures of the catalytic domains of type III alcohol dehydrogenase and membrane glucose dehydrogenase have been modelled successfully on the methanol dehydrogenase structure (determined by X-ray crystallography). Their mechanisms are likely to be similar in many ways and probably always involve a calcium ion (or other divalent cation) at the active site. The electron transport chains involving the soluble alcohol dehydrogenases usually consist only of soluble c-type cytochromes and the appropriate terminal oxidases. The membrane-bound quinohaemoprotein alcohol dehydrogenases pass electrons to membrane ubiquinone which is then oxidized directly by ubiquinol oxidases. The electron acceptor for membrane glucose dehydrogenase is ubiquinone which is subsequently oxidized directly by ubiquinol oxidases or by electron transfer chains involving cytochrome bcl, cytochrome c and cytochrome c oxidases. The function of most of these systems is to produce energy for growth on alcohol or aldose substrates, but there is some debate about the function of glucose dehydrogenases in those bacteria which contain one or more alternative pathways for glucose utilization. Synthesis of the quinoprotein respiratory systems requires production of PQQ, haem and the dehydrogenase subunits, transport of these into the periplasm, and incorporation together with divalent cations, into active quinoproteins and quinohaemoproteins. Six genes required for regulation of synthesis of methanol dehydrogenase have been identified in *Methylobacterium*, and there is evidence that two, two-component regulatory systems are involved.

L5 ANSWER 3 OF 15 MEDLINE on STN  
 ACCESSION NUMBER: 1993286127 MEDLINE Full-text  
 DOCUMENT NUMBER: PubMed ID: 8509415  
 TITLE: Topological analysis of quinoprotein glucose

dehydrogenase in Escherichia coli and its ubiquinone-binding site.

AUTHOR: Yamada M; Sumi K; Matsushita K; Adachi O; Yamada Y

CORPORATE SOURCE: Department of Biological Chemistry, Faculty of Agriculture, Yamaguchi University, Japan.

SOURCE: The Journal of biological chemistry, (1993 Jun 15) Vol. 268, No. 17, pp. 12812-7.  
Journal code: 2985121R. ISSN: 0021-9258. L-ISSN: 0021-9258.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199307

ENTRY DATE: Entered STN: 23 Jul 1993  
Last Updated on STN: 3 Feb 1997  
Entered Medline: 13 Jul 1993

AB Topological structure of quinoprotein glucose dehydrogenase in the inner membrane of Escherichia coli was determined by constructing protein fusions with alkaline phosphatase or beta-galactosidase. Analysis of the fusions revealed that the dehydrogenase possesses five membrane-spanning segments, and the N-terminal and C-terminal portions resided at the cytoplasmic and periplasmic side of the membrane, respectively. These results agreed with the hydropathy profile based on its primary structure. The topological structure suggests that the predicted binding site of the prosthetic group pyrroloquinoline quinone is located at the periplasmic side and that the amino acid residues corresponding to those that were presumed to interact with ubiquinone in one subunit of mitochondrial NADH dehydrogenase also occur at the periplasmic side. When the purified glucose dehydrogenase and cytochrome o ubiquinol oxidase were reconstituted together with ubiquinone into liposomes, a membrane potential could be generated by the electron transfer at the site of the ubiquinol oxidase but not of the dehydrogenase. These results suggest that glucose dehydrogenase has a ubiquinone reacting site close to the periplasmic side of the membrane, and thus its electron transfer to ubiquinone appears to be incapable of forming a proton electrochemical gradient across the inner membrane of E. coli.

L5 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1081076 HCAPLUS Full-text

DOCUMENT NUMBER: 151:334261

TITLE: MicroRNA miR-15a/16-1 modulated genes (gene signatures) associated with human chronic lymphocytic leukemia (CCL) and uses thereof

INVENTOR(S): Croce, Carlo M.; Calin, George A.

PATENT ASSIGNEE(S): The Ohio State University Research Foundation, USA

SOURCE: PCT Int. Appl., 256 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2009108856	A2	20090903	WO 2009-US35463	20090227
WO 2009108856	A3	20100114		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,			

KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,  
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,  
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,  
 IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,  
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
 TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
 ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2008-67406P P 20080228

AB Methods and compns. for the diagnosis, prognosis and/or treatment of leukemia associated diseases are disclosed. Specifically, a high-throughput profiling of genes modulated by miR-15a/16-1 in a leukemic cell line model (MEG-01) and in primary CLL samples are produced. By combining exptl. and bioinformatics data, a miR-15a/16-1-gene signature in leukemic cells is identified. By examining the Gene Ontol. (GO) database, a significant enrichment in cancer genes (such as MCL1, BCL2, ETS1, or JUN) that directly or indirectly affect apoptosis and cell cycle is found. Among the components of the miR-15a/16-1 signature, a statistically significant enrichment in AU-rich elements (AREs) is observed

L5 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1334623 HCAPLUS Full-text

DOCUMENT NUMBER: 150:1841

TITLE: Construction and Characterization of Direct Electron Transfer-Type Continuous Glucose Monitoring System Employing Thermostable Glucose Dehydrogenase Complex

AUTHOR(S): Yamazaki, Tomohiko; Okuda-Shimazaki, Junko; Sakata, Chikako; Tsuya, Taiki; Sode, Koji

CORPORATE SOURCE: Biomaterials Center, National Institute for Materials Science (NIMS), Namiki, Tsukuba, Ibaraki, Japan

SOURCE: Analytical Letters (2008), 41(13), 2363-2373  
 CODEN: ANALBP; ISSN: 0003-2719

PUBLISHER: Taylor & Francis, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We demonstrated a direct electron transfer-type enzyme electrode using thermostable FAD-glucose dehydrogenase (FADGDH) consisting of three distinct subunits (an FAD-containing catalytic subunit, a cytochrome subunit, and a chaperone-like subunit) and its application in developing a continuous glucose monitoring (CGM) system without a synthetic electron mediator. An FADGDH-immobilized electrode showed current signals according to glucose concentration in the absence of a synthetic electron mediator. The sensor containing the FADGDH complex showed a stable response for 72 h at 37°. Furthermore, the CGM response was well fitted to the gradient change in the glucose concentration obtained from system calibration.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:1349195 HCAPLUS Full-text

DOCUMENT NUMBER: 146:141179

TITLE: Production and application of plasmid pET28a(+)-P450BM3-gdh0310 in bioconversion of indole to indigo

INVENTOR(S): Mei, Yuehe; Lu, Yan

PATENT ASSIGNEE(S): Zhejiang University, Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 17pp.

DOCUMENT TYPE: CODEN: CNXXEV  
 LANGUAGE: Patent  
 Chinese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 1880459	A	20061220	CN 2006-10050388	20060418
CN 100429314	C	20081029		

PRIORITY APPLN. INFO.: CN 2006-10050388 20060418

AB The title plasmid pET28a(+)-P450BM3-gdh0310 is produced by inserting P 450 BM3 gene and glucose dehydrogenase gene into pET28a(+) expression vector. After transferring the recombinant plasmid into E. coli BL21, the recombinant bacterial strain can express cytochrome P 450 monooxygenase and glucose dehydrogenase. The invention discloses the sequence from the promoter of P 450 BM3 gene to the terminator of glucose dehydrogenase gene. The recombinant bacterial strain can cooperatively catalyzing the bioconversion of indole to indigo with an increased catalytic activity (22-27 times). The invention can be expected to use for manufacturing indigo dye by bioconversion.

L5 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:120414 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 144:184702

TITLE: Gene expression profiles for identifying patients at risk of developing encephalitis following immunotherapy for Alzheimer's disease

INVENTOR(S): O'Toole, Margot; Dorner, Andrew J.; Janszen, Derek B.; Slonim, Donna K.; Mounts, William M.; Reddy, Padmalatha S.; Hill, Andrew A.

PATENT ASSIGNEE(S): Wyeth, USA

SOURCE: PCT Int. Appl., 298 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2006014755	A2	20060209	WO 2005-US25771	20050720
WO 2006014755	A3	20060413		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2571856	A1	20060209	CA 2005-2571856	20050720
US 20060073496	A1	20060406	US 2005-186236	20050720
EP 1784509	A2	20070516	EP 2005-795582	20050720
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: US 2004-589877P P 20040720  
 US 2005-672716P P 20050418  
 WO 2005-US25771 W 20050720

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention generally relates to a method for an improved treatment for Alzheimer's disease (AD) using immunotherapy, e.g., immunotherapy targeting  $\beta$  amyloid (A $\beta$ ) and immunotherapy based on AN1792. By ANOVA and GeneCluster analyses of Affymetrix U133A GeneChip data, statistically significant assocns. were detected between the gene expression profiles of peripheral blood mononuclear cells of patients prior to immunization with AN1792 and the post-immunization development of encephalitis. In addition, statistically significant assocns. were found between the pre-immunization gene expression profile in PBMCs and post-immunization development of IgG response. The method allows for predicting an adverse clin. response, and therefore allows for an improved safety profile of AN1792. In another embodiment, the method allows for predicting a favorable clin. response, and therefore allows for an improved efficacy profile of AN1792. The methods of the present invention may be combined to predict a favorable clin. response and the lack of an adverse clin. response.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
 (4 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:1154777 HCAPLUS Full-text

DOCUMENT NUMBER: 143:433974

TITLE: Gene expression profiling and markers for use in the  
 assessment of hepatotoxicity

INVENTOR(S): Porter, Mark; Higgs, Brandon; Mendrick, Donna;  
 Elashoff, Michael

PATENT ASSIGNEE(S): Gene Logic, Inc., USA

SOURCE: PCT Int. Appl., 264 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005100989	A2	20051027	WO 2005-US11532	20050407
WO 2005100989	A3	20061130		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2562343	A1	20051027	CA 2005-2562343	20050407
EP 1751303	A2	20070214	EP 2005-736350	20050407
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
JP 2007533005	T	20071115	JP 2007-507445	20050407

PRIORITY APPLN. INFO.:

US 2004-559949P P 20040407  
WO 2005-US11532 W 20050407

AB Methods of using the effects of a substance on gene expression profiles are described for use in assessing their toxicity, especially hepatotoxicity, are described. The invention also includes microarrays, computer systems comprising the toxicity prediction models, as well as methods of using the computer systems by remote users for determining the toxicity of test agents. A database of gene expression profiles for rat liver using a broad range of drugs, com. chems., and known poisons is developed. OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:1020555 HCAPLUS Full-text

DOCUMENT NUMBER: 143:320266

TITLE: Genes with differential expression profile between human dental pulp stem cells and mesenchymal stem cells and use for regenerating tooth germ

INVENTOR(S): Ueda, Minoru; Yamada, Yoichi

PATENT ASSIGNEE(S): Hitachi Medical Corp., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 246 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005253442	A	20050922	JP 2004-111582	20040309
PRIORITY APPLN. INFO.:			JP 2004-111582	20040309

AB The present invention relates to a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells, as well as a method for regenerating tooth germ using these genes. According to the present invention, the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cell were revealed, and a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells was identified. By utilizing the groups of the genes of the present invention together with the dental pulp stem cells and mesenchymal stem cells, hard tissue such as tooth germ, dental pulp, dentin or bone can be regenerated. The present inventors investigated the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cells, resp. At first, the present inventors confirmed the differential expression of Alkaline phosphatase (ALP) activity, Dentin matrix protein 1 (DMP 1), Dentin phosphosialoprotein (DSPP) using by real time reverse-transcriptase polymerase chain reaction (RT-PCR) in total RNA from primary cultures. The number of genes in hDPSCs(I) that were up-regulated by 2>-fold, compared to hMSCs, was 614 (Table, IV). On the other hand, the number of genes down regulated by <2-fold in hDPSCs (I) was 296 (Table III, IV).

L5 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:300480 HCAPLUS Full-text

DOCUMENT NUMBER: 142:370305

TITLE: Glucose dehydrogenase/



cytochrome fusion protein for  
glucose sensor  
INVENTOR(S): Sode, Koji  
PATENT ASSIGNEE(S): Japan  
SOURCE: PCT Int. Appl., 34 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030807	A1	20050407	WO 2004-JP14575	20040928
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
GB 2421951	A	20060712	GB 2006-6955	20040928
GB 2421951	B	20080227		
US 20070267301	A1	20071122	US 2006-574085	20060330
PRIORITY APPLN. INFO.:			JP 2003-340092	A 20030930
			WO 2004-JP14575	W 20040928

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A pyrroloquinolinequinone glucose dehydrogenase ( PQQGDH)/cytochrome fusion protein is disclosed. As PQQGDH, an use can be made of, for example, water-soluble PQQGDH derived from Acinetobacter calcoaceticus. As cytochrome, an use can be made of, for example, an electron transport domain of quinoximoprotein ethanol dehydrogenase of Comamonas testosteroni. In this fusion protein, an intramol. electron transfer from PQQ being an oxidation-reduction center to cytochrome occurs. Accordingly, a direct electron transport-type glucose sensor not needing any electron mediator can be produced by the use of the fusion protein.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:702629 HCAPLUS Full-text

DOCUMENT NUMBER: 142:151093

TITLE: Engineered PQQ glucose dehydrogenase

-based enzyme sensor for continuous glucose monitoring  
Okuda, Junko; Wakai, Junko; Igarashi, Satoshi; Sode, Koji

CORPORATE SOURCE: Department of Biotechnology, Faculty of Technology,  
Tokyo University of Agriculture and Technology, Tokyo,  
Japan

SOURCE: Analytical Letters (2004), 37(9), 1847-1857

CODEN: ANALBP; ISSN: 0003-2719

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Continuous glucose monitoring (CGM) is expected to become an ideal way to monitor the glycemic level of diabetic patients. A recent trend in the disposable

self blood glucose sensing development has been the use of pyrroloquinoline quinone-harboring glucose dehydrogenase (PQQGDH). However, due to a number of limitations of PQQGDH, conventionally utilized glucose oxidase (GOD) remains widely utilized in CGM. Two major problems that arose in the application of PQQGDH for CGM are the poor stability and its requirement for artificial electron acceptors for electrochem. measurement. To solve these problems, we investigated the amenability of our engineered PQQGDH Ser415Cys, which has a far superior thermal stability over the wild-type enzyme, for the CGM system, and the applicability of cyt b562 as the electron mediator to construct a CGM system free of synthetic mediator. As a result, the operational stability of CGM system employing Ser415Cys co-immobilized with cyt b562 was far superior to that of the wild-type enzyme-based electrode, with more than 60% of the initial response observed after 72 h at 37°. We achieved the successful application of PQQGDH in continuous operation without a significant decrease in the sensor signal. OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD

(4 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:542873 HCAPLUS Full-text

DOCUMENT NUMBER: 141:273433

TITLE: Molecular engineering of PQQGDH and its applications

AUTHOR(S): Igarashi, Satoshi; Okuda, Junko; Ikebukuro, Kazunori; Sode, Koji

CORPORATE SOURCE: National Institute for Materials Science, 1-1, Namiki, Tsukuba, Ibaraki, 305-0044, Japan

SOURCE: Archives of Biochemistry and Biophysics (2004), 428(1), 52-63

CODEN: ABBIA4; ISSN: 0003-9861

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Pyrroloquinolinequinone glucose dehydrogenases (PQQGDHs) are the most industrially attractive enzymes, especially PQQGDH-B employing glucose sensors are already in the market. To develop an ideal glucose sensor enzyme, therefore we have constructed and characterized several engineered PQQGDH-Bs. The engineered enzymes will give effective information about unknown properties on PQQGDH-B such as reaction mechanism, substrate inhibition system, and neg. cooperativity. Of equal importance, the application of the thermostable PQQGDH-B is not limited to the development of continuous glucose monitoring system, biofuel cell, and DNA sensors. In addition, co-immobilizing electron transfer protein such as cytochrome c and cytochrome b562, we have developed the sensor system that showed 30-fold greater response. Furthermore, mimicking the domain structure of QH-EDH, we constructed fusion protein, QH-GDH, allowing the construction of a direct electron transfer-type glucose sensor. To the future, combining the engineered PQQGDH-B with the application of cytochromes instead of artificial electron mediator, we will construct and develop the ideal glucose sensor and other applications.

OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:293978 HCAPLUS Full-text

DOCUMENT NUMBER: 136:337341

TITLE: Materials and methods to modulate ligand binding/enzymic activity of  $\alpha/\beta$  proteins containing an allosteric regulatory site

INVENTOR(S): Stauton, Donald E.  
 PATENT ASSIGNEE(S): Icos Corporation, USA  
 SOURCE: PCT Int. Appl., 163 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002031511	A2	20020418	WO 2001-US32047	20011012
WO 2002031511	A3	20030313		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2425581	A1	20020418	CA 2001-2425581	20011012
AU 2002013196	A	20020422	AU 2002-13196	20011012
US 20030088061	A1	20030508	US 2001-976935	20011012
EP 1325341	A2	20030709	EP 2001-981560	20011012
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004511496	T	20040415	JP 2002-534845	20011012
MX 2003003207	A	20040326	MX 2003-3207	20030411
PRIORITY APPLN. INFO.:			US 2000-239750P	P 20001012
			WO 2001-US32047	W 20011012

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods of modulating binding between an  $\alpha/\beta$  protein and a binding partner are provided, along with methods of identifying modulators and their use. The methods comprise contacting the  $\alpha/\beta$  protein with an allosteric effector mol. which binds to an allosteric site of the  $\alpha/\beta$  protein and alters the conformation of the  $\alpha/\beta$  protein such that the binding of the  $\alpha/\beta$  protein to a binding partner is modulated. Thus, a primary screen for inhibitors of the classical pathway complement protein C2 and alternative pathway complement protein factor B involving modifications of standard hemolytic CH50 and AH50 assays in a microtiter plate format was carried out. Lead compds. identified in this screen were submitted to a second screening using purified complement proteins to determine which stage of complement activation the compds. inhibited. Five diaryl sulfides were identified. Numerous other assays, e.g., to identify inhibitors of integrin  $\alpha\text{E}\beta$  interaction with E cadherin, inhibitors of Rac1 GDP-GTP exchange, or antagonists of E. coli 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase, were conducted as well. OS.CITING REF COUNT: 5  
 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
 (5 CITINGS)

L5 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:473659 HCAPLUS Full-text

DOCUMENT NUMBER: 135:205729

TITLE: Microarray analysis of the in vivo effects of hypophysectomy and growth hormone treatment on gene expression in the rat

AUTHOR(S): Flores-Morales, Amilcar; Stahlberg, Nina; Tollet-Egnell, Petra; Lundberg, Joakim; Malek, Renae L.; Quackenbush, John; Lee, Norman H.; Norstedt,

Gunnar  
 CORPORATE SOURCE: Department of Molecular Medicine, Karolinska  
 Institute, Stockholm, 17176, Swed.  
 SOURCE: Endocrinology (2001), 142(7), 3163-3176  
 CODEN: ENDOAO; ISSN: 0013-7227  
 PUBLISHER: Endocrine Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The authors used cDNA microarrays containing 3000 different rat genes to study the consequences of severe hormonal deficiency (hypophysectomy) on the gene expression patterns in heart, liver, and kidney. Hybridization signals were seen from a majority of the arrayed cDNAs; nonetheless, tissue-specific expression patterns could be delineated. Hypophysectomy affected the expression of genes involved in a variety of cellular functions. Between 16-29% of the detected transcripts from each tissue changed expression level as a reaction to this condition. Chronic treatment of hypophysectomized animals with human GH also caused significant changes in gene expression patterns. The study confirms previous knowledge concerning certain gene expression changes in the above-mentioned situations and provides new information regarding hypophysectomy and chronic human GH effects in the rat. Furthermore, the authors have identified several new genes that respond to GH treatment. The results represent a first step toward a more global understanding of gene expression changes in states of hormonal deficiency.

OS.CITING REF COUNT: 65 THERE ARE 65 CAPLUS RECORDS THAT CITE THIS  
 RECORD (65 CITINGS)

REFERENCE COUNT: 92 THERE ARE 92 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 15 SCISEARCH COPYRIGHT (c) 2010 The Thomson Corporation on  
 STN

ACCESSION NUMBER: 2001:252029 SCISEARCH Full-text  
 THE GENUINE ARTICLE: 412TM

TITLE: Transmembrane orientation and topology of the NADH :  
 quinone oxidoreductase putative quinone binding subunit  
 NuoH

AUTHOR: Hagerhall C (Reprint)  
 CORPORATE SOURCE: Univ Lund, Dept Biochem, S-22100 Lund, Sweden (Reprint)  
 AUTHOR: Roth R  
 COUNTRY OF AUTHOR: Sweden  
 SOURCE: BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, (2 APR 2001)  
 Vol. 1504, No. 2-3, pp. 352-362.  
 ISSN: 0005-2728.

PUBLISHER: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM,  
 NETHERLANDS.

DOCUMENT TYPE: Article; Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 45  
 ENTRY DATE: Entered STN: 6 Apr 2001  
 Last Updated on STN: 6 Apr 2001

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB NADH:quinone oxidoreductase, or Complex I, is a multi-subunit membrane-bound enzyme in the respiratory chain of many pro- and eukaryotes. The enzyme catalyzes the oxidation of NADH and donates electrons to the quinone pool, coupled to proton translocation across the membrane, but the mechanism of energy transduction is not understood. In bacteria the enzyme consists of 14 subunits, seven membrane spanning and seven protruding from the membrane. The hydrophobic NuoH (NQO8, ND1, NdhA) subunit is seemingly involved in quinone binding. A homologous, structurally and most likely functionally similar subunit is also found in F420H2 oxidoreductases and in complex membrane-bound hydrogenases. We have made theoretical analyses of NuoH and NuoH-like polypeptides and experimentally analyzed the

transmembrane topology of the NuoH subunit from *Rhodobacter capsulatus* by constructing and analyzing alkaline phosphatase fusion proteins. This demonstrated that the NuoH polypeptide has eight transmembrane segments, and four highly conserved hydrophilic sequence motifs facing the inside, bacterial cytoplasm. The N-terminal and C-terminal ends are located on the outside of the membrane. A topology model of NuoH based on these results is presented, and implications from the model are discussed. (C) 2001 Elsevier Science B.V. All rights reserved.

=> d his

(FILE 'HOME' ENTERED AT 13:54:27 ON 21 JUN 2010)

FILE 'MEDLINE, HCAPLUS, BIOSIS, BIOTECHDS, SCISEARCH, EMBASE' ENTERED AT 13:55:14 ON 21 JUN 2010

```
L1      24 S (PYRROLOQUINOLINE QUINONE GLUCOSE DEHYDROGENASE OR PQQGDH) AN
L2      11 DUP REM L1 (13 DUPLICATES REMOVED)
L3      432 S (GLUCOSE DEHYDROGENASE OR PQQGDH) AND CYTOCHROME
L4      251 DUP REM L3 (181 DUPLICATES REMOVED)
L5      15 S L4 AND FUSION
```

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	105.07	105.29
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-16.15	-16.15

STN INTERNATIONAL LOGOFF AT 14:05:02 ON 21 JUN 2010